John Evans (@john_evans3) / X

John Evans

3,726 posts

John Evans

@john_evans3

CEO, Beam Therapeutics. We are working on creating precision genetic medicines using base editing. (tweets are my own)

Joined February 2012

Pinned
John Evans
@john_evans3
Mar 10, 2025
Wonderful NYT story about our BEAM-302 data in @nytimes @ginakolata provides a clear summary of the significance of this data, along with perspectives from leaders in the AATD and genetic disease fields We will accelerate this program for patients
Mutated DNA Restored to Normal in Gene Therapy Advance (Published 2025)
From nytimes.com
5K
John Evans
@john_evans3
Jan 10, 2022
Beam has entered a new collaboration with Pfizer for in vivo base editing! $300M upfront, >$1B milestones, 3 new targets (one each in liver, muscle, and CNS), plus a 35% WW co-co option on any one program at the end of P1/2:
globenewswire.com
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base...
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid...
John Evans
@john_evans3
Sep 7, 2022
Very excited to announce a new deal this morning! We are launching a newco, Orbital, to develop next-gen RNA therapies. Orbital combines Beam technology/team + add'l RNA technologies + IP from Stanford + leading RNA founders + initial investment from ARCH a16z & Newpath.
John Evans
@john_evans3
Sep 5, 2023
Excited to announce that in August we dosed our first patient in the BEAM-201 trial! This is the first patient treated for Beam and the first patient in the US treated with a base editing therapeutic.
globenewswire.com
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed,...
BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing...
42K
John Evans
@john_evans3
Jan 26, 2022
Beam mentioned twice in this Nature review of 7 technologies to watch in 2022: once for base editing, and once for LNPs for delivery beyond the liver. h/t: @zhaoweiasu nature.com/articles/d4158…
John Evans
@john_evans3
Dec 11, 2022
Inspiring and hopeful clinical case out of England - and the first human clinical proof of concept for base editing!! bbc.com/news/health-63…
John Evans
@john_evans3
Mar 10, 2025
Privileged to share initial data for BEAM-302 today in alpha-1 antitrypsin deficiency (AATD)! AATD is a severe, progressive disease impacting both lung and liver function that affects 100,000 people in the US
globenewswire.com
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1...
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and...
45K
John Evans
@john_evans3
Jan 9, 2023
A big year ahead for Beam and base editing! This year, we will begin treating patients in the US with sickle cell disease and acute leukemia with BEAM-101 and BEAM-201, respectively.
globenewswire.com
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated...
BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 ...
31K
John Evans
@john_evans3
Nov 8, 2021
Excited to report our latest progress in our 3Q filing! Most importantly, the BEAM-101 IND is now open, designated safe to proceed by the FDA. BEAM-102 IND-enabling studies are also underway.
globenewswire.com
Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial...
BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 08,...
John Evans
@john_evans3
Dec 2, 2022
Green light received from FDA for BEAM-201 IND Now on to the clinic and patients with relapsed/refractory T-cell acute leukemia
globenewswire.com
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug...
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines...
John Evans
@john_evans3
Jan 9, 2022
Excited to share Beam pipeline updates here:
globenewswire.com
Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics...
First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301...
John Evans
@john_evans3
Feb 23, 2021
Very excited to welcome the Guide team and technology to Beam! Guide is working on next-gen nonviral LNP delivery to organs beyond the liver. Our goal together will be to significantly expand the potential application space for in vivo gene editing.
globenewswire.com
Beam Therapeutics Announces Acquisition of Guide Therapeutics
GuideTx’s Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing...
John Evans
@john_evans3
Jul 13, 2021
Prime Medicine launches today! Beam helped start the company and shares technology with Prime. Congrats to David Keith Andrew Jeremy Meredith Karen and the entire Prime team. Very excited to see what prime editing can do for patients.
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
From prnewswire.com
John Evans
@john_evans3
Nov 12, 2023
Congratulations to Verve Therapeutics for the first human data with an in vivo base editor, VERVE-101 targeting PCSK9 for cardiovascular disease (CVD)! It’s a hugely important milestone for the field: ir.vervetx.com/news-releases/…
16K